These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 20101210)

  • 41. A computational approach for investigating the mutational landscape of RAC-alpha serine/threonine-protein kinase (AKT1) and screening inhibitors against the oncogenic E17K mutation causing breast cancer.
    Thirumal Kumar D; Jain N; Evangeline J; Kamaraj B; Siva R; Zayed H; George Priya Doss C
    Comput Biol Med; 2019 Dec; 115():103513. PubMed ID: 31698236
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PIK3CA hotspot mutations p. H1047R and p. H1047L sensitize breast cancer cells to thymoquinone treatment by regulating the PI3K/Akt1 pathway.
    Zhou J; Imani S; Shasaltaneh MD; Liu S; Lu T; Fu J
    Mol Biol Rep; 2022 Mar; 49(3):1799-1816. PubMed ID: 34816327
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation.
    Wang GM; Wong HY; Konishi H; Blair BG; Abukhdeir AM; Gustin JP; Rosen DM; Denmeade SR; Rasheed Z; Matsui W; Garay JP; Mohseni M; Higgins MJ; Cidado J; Jelovac D; Croessmann S; Cochran RL; Karnan S; Konishi Y; Ota A; Hosokawa Y; Argani P; Lauring J; Park BH
    Cancer Res; 2013 Jun; 73(11):3248-61. PubMed ID: 23580570
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations.
    Lee JB; Jung M; Beom SH; Kim GM; Kim HR; Choi HJ; Sohn JH; Ahn JB; Rha SY; Chung HC
    Invest New Drugs; 2021 Oct; 39(5):1366-1374. PubMed ID: 33723724
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.
    Yu Y; Savage RE; Eathiraj S; Meade J; Wick MJ; Hall T; Abbadessa G; Schwartz B
    PLoS One; 2015; 10(10):e0140479. PubMed ID: 26469692
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data.
    Zardavas D; Phillips WA; Loi S
    Breast Cancer Res; 2014 Jan; 16(1):201. PubMed ID: 25192370
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PIK3CA mutations in mucinous cystic neoplasms of the pancreas.
    Garcia-Carracedo D; Chen ZM; Qiu W; Huang AS; Tang SM; Hruban RH; Su GH
    Pancreas; 2014 Mar; 43(2):245-9. PubMed ID: 24518503
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.
    Xing Y; Lin NU; Maurer MA; Chen H; Mahvash A; Sahin A; Akcakanat A; Li Y; Abramson V; Litton J; Chavez-MacGregor M; Valero V; Piha-Paul SA; Hong D; Do KA; Tarco E; Riall D; Eterovic AK; Wulf GM; Cantley LC; Mills GB; Doyle LA; Winer E; Hortobagyi GN; Gonzalez-Angulo AM; Meric-Bernstam F
    Breast Cancer Res; 2019 Jul; 21(1):78. PubMed ID: 31277699
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
    Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M
    Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PIK3CA alterations in Middle Eastern ovarian cancers.
    Abubaker J; Bavi P; Al-Haqawi W; Jehan Z; Munkarah A; Uddin S; Al-Kuraya KS
    Mol Cancer; 2009 Jul; 8():51. PubMed ID: 19638206
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells.
    Yi YW; Kang HJ; Kim HJ; Hwang JS; Wang A; Bae I
    Mol Carcinog; 2013 Sep; 52(9):667-75. PubMed ID: 22488590
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hotspot mutation profiles of AKT1 in Asian women with breast and endometrial cancers.
    Shimoi T; Hashimoto J; Sudo K; Shimomura A; Noguchi E; Shimizu C; Yunokawa M; Yonemori K; Yoshida H; Yoshida M; Kato T; Kinoshita T; Fukuda T; Fujiwara Y; Tamura K
    BMC Cancer; 2021 Oct; 21(1):1131. PubMed ID: 34670536
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.
    Fujimoto Y; Morita TY; Ohashi A; Haeno H; Hakozaki Y; Fujii M; Kashima Y; Kobayashi SS; Mukohara T
    Sci Rep; 2020 Dec; 10(1):21762. PubMed ID: 33303839
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Frequent PIK3CA-activating mutations in hidradenoma papilliferums.
    Liau JY; Lan J; Hong JB; Tsai JH; Kuo KT; Chu CY; Sheen YS; Huang WC
    Hum Pathol; 2016 Sep; 55():57-62. PubMed ID: 27184479
    [TBL] [Abstract][Full Text] [Related]  

  • 55. AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma.
    Cohen Y; Shalmon B; Korach J; Barshack I; Fridman E; Rechavi G
    Gynecol Oncol; 2010 Jan; 116(1):88-91. PubMed ID: 19853286
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA.
    Kim JS; Lee C; Bonifant CL; Ressom H; Waldman T
    Mol Cell Biol; 2007 Jan; 27(2):662-77. PubMed ID: 17060456
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness.
    Tserga A; Chatziandreou I; Michalopoulos NV; Patsouris E; Saetta AA
    Virchows Arch; 2016 Jul; 469(1):35-43. PubMed ID: 27059323
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Downregulation of BAG‑1 in T47D cells promotes resistance to tamoxifen via activation of the PI3K/Akt/mTOR signaling pathway.
    Lu S; Du Y; Cui F; Feng X; Ma Y; Liu H
    Oncol Rep; 2019 Mar; 41(3):1901-1910. PubMed ID: 30747221
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
    Araki K; Miyoshi Y
    Breast Cancer; 2018 Jul; 25(4):392-401. PubMed ID: 29086897
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
    Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.